1 research outputs found
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients.
This study was aimed to analyze the impact of cardiovascular disease on this population. Materials
& methods: EMIR was a multicenter, prospective study, including 1433 AF patients taking rivaroxaban
for ≥6 months. Data were analyzed according to the presence of vascular disease. Results: Coronary
artery disease was detected in 16.4%, peripheral artery disease/aortic plaque in 6.7%, vascular disease
in 28.3%. Patients with coronary artery disease had higher rates (per 100 patient-years) of major adverse
cardiovascular events (2.98 vs 0.71; p < 0.001) and cardiovascular death (1.79 vs 0.41; p = 0.004). Those
with vascular disease had higher rates of thromboembolic events (1.47 vs 0.44; p = 0.007), major adverse
cardiovascular events (2.03 vs 0.70; p = 0.004), and cardiovascular death (1.24 vs 0.39; p = 0.025). Patients
with peripheral artery disease/aortic plaque had similar rates. Conclusion: AF patients with vascular
disease have a higher risk of non-embolic outcomes